Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2014

01-11-2014 | Special Feature

Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan

Author: Hiroko Bando

Published in: Breast Cancer | Issue 6/2014

Login to get access

Abstract

About 5–10 % of breast cancer cases are considered to be hereditary, and germ line mutations in the BRCA1 and BRCA2 genes have been proven to contribute to the development of hereditary breast and/or ovarian cancer syndrome (HBOC). Breast cancer diagnosed at a young age is an indication of a higher likelihood of HBOC. Risk assessment, genetic counseling, and BRCA1/BRCA2 mutation testing, especially for younger women with breast cancer, have started to be an integral element of practice due to advances in gene sequencing technologies and accumulating evidence for the clinical implications of BRCA mutation status for not only early breast cancer management, but also for the patient’s own and their family’s next cancer risk, and proactive steps toward a risk-reducing approach. As yet, the cancer genetic service system is immature in Japan. There are several problems to be solved to improve cancer genetic services in clinical practice for breast cancer.
Literature
1.
2.
Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;12:937–48.CrossRef
3.
4.
Ruddy KJ, Gelber S, Shin J, Garber JE, Rosenberg R, Przypysny M, et al. Genetic testing in young women with breast cancer: results from a web-based survey. Ann Oncol. 2009;21:741–7.PubMedCrossRef
5.
US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143:355–61.CrossRef
6.
Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45:425–31.PubMedCrossRef
7.
Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151–61.PubMedCrossRef
8.
Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013;22:155–63.PubMedCrossRef
9.
Bellcross CA, Kolor K, Goddard KAB, Coates RJ, Reyes M, Khoury MJ. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med. 2011;40:61–6.PubMedCrossRef
10.
Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CH, Lishner DM, et al. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117:5334–43.PubMedCrossRef
11.
Zilliacus E, Meiser B, Gleeson M, Watts K, Tucker K, Lobb EA, et al. Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer. Support Care Cancer. 2012;20:2949–58. doi:10.​1007/​s00520-012-1427-6.PubMedCrossRef
12.
Tung N. Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA. 2011;305:2211–20.PubMedCrossRef
13.
Pierce LJ, Phillips K-A, Griffith KA, Buys S, Gaffney DK, Moran MS, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121:389–98.PubMedCrossRefPubMedCentral
14.
Evans DGR, Moran A, Hartley R, Dawson J, Bulman B, Knox F, et al. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer. 2010;102:1091–8.PubMedCrossRefPubMedCentral
15.
Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104:1384–92.PubMedCrossRefPubMedCentral
16.
Heemskerk-Gerritsen B. Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease-free survival and overall survival [abstract]? Eur J Cancer. 2010;8:s206.CrossRef
17.
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44.PubMedCrossRef
18.
Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL. The role of poly adenosine disphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. Asia Pac J Clin Oncol. 2011;7:197–211.PubMedCrossRef
19.
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539–48.PubMedCrossRef
20.
Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999;59:2011–7.PubMed
21.
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.PubMedCrossRef
22.
Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28:4214–20.PubMedCrossRef
23.
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–47.PubMedCrossRefPubMedCentral
24.
Klee E, Hoppman-Chaney N, Ferber M. Expanding DNA diagnostic panel testing: is more better? Expert Rev. Mol Diagn. 2011;11:703–9.
25.
26.
McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938–43.PubMed
27.
Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23:4275–86.PubMedCrossRef
28.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.PubMedCrossRefPubMedCentral
29.
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331–7.PubMedCrossRefPubMedCentral
30.
Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.PubMedCrossRef
31.
Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Hereditary Breast Cancer Clinical Study Group, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093–7.PubMedCrossRef
32.
Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin. 2011. doi:10.​3322/​caac.​20128.PubMedPubMedCentral
33.
Bowen D, McTiernan A, Burke W, Powers D, Pruski J, Durfy S, et al. Participation in breast cancer risk counseling among women with a family history. Cancer Epidemiol Biomarkers Prev. 1999;8:581–5.PubMed
34.
Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: psychological aspects and implications. J Consult Clin Psychol. 2002;70:784–97.PubMedCrossRef
35.
Ropka ME, Wenzel J, Phillips EK, Siadaty M, Philbrick JT. Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomark Prev. 2006;15:840–55.CrossRef
36.
Pasacreta JV. Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: an integrative review. Cancer Invest. 2003;21:588–623.PubMedCrossRef
37.
Ryan EL, Skinner CS. Risk beliefs and interest in counseling: focus-group interviews among first-degree relatives of breast cancer patients. J Cancer Educ. 1999;14:99–103.PubMed
38.
Gil F, Méndez I, Sirgo A, Llort G, Blanco I, Cortés-Funes H. Perception of breast cancer risk and surveillance behaviours of women with family history of breast cancer: a brief report on a Spanish cohort. Psychooncology. 2003;12:821–7.PubMedCrossRef
39.
Schlich-Bakker KJ, ten Kroode HF, Ausems MG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns. 2006;62:13–20.PubMedCrossRef
40.
McAllister M, Davies L, Payne K, Nicholls S, Donnai D, MacLeod R. The emotional effects of genetic diseases: implications for clinical genetics. Am J Med Genet A. 2007;143A:2651–61.PubMedCrossRef
41.
Ando N, Iwamitsu Y, Kuranami M, Okazaki S, Yamamoto K, Watanabe M, et al. Concerns about inherited risk of breast cancer prior to diagnosis in Japanese patients with breast complaints. Fam Cancer. 2011;10:681–9.PubMedCrossRef
42.
Ritvo P, Edwards SA, Glendon G, Mirea L, Knight JA, Andrulis IL, et al. Beliefs about optimal age and screening frequency predict breast screening adherence in a prospective study of female relatives from the Ontario site of the Breast Cancer Family Registry. BMC Public Health. 2012;12:518.PubMedCrossRefPubMedCentral
43.
Matloff ET, Moyer A, Shannon KM, Niendorf KB, Col NF. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making. J Womens Health (Larchmt). 2006;15(7):843–56.CrossRef
44.
Ardern-Jones A, Kenen R, Eeles R. Too much too soon? Patientsʼ and health professionalsʼ views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care. 2005;14:272–81.CrossRef
45.
Schwartz MD, Lerman C, Brogan B, Peshkin BN, Hughes Halbert C, DeMarco T, et al. Impact of BRCA1/2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823–9.PubMedCrossRef
46.
Schwartz MD, Lerman C, Brogan B, Peshkin BN, Isaacs C, DeMarco T, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:1003–7.PubMedCrossRef
47.
Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol. 2007;25:285–91.PubMedCrossRef
48.
Schlich-Bakker KJ, Wárlám-Rodenhuis CC, van Echtelt J, van den Bout J, Ausems MG, ten Kroode HF. Short-term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42:2722–8.PubMedCrossRef
49.
Meiser B, Gleeson M, Watts K, Peate M, Zilliacus E, Barlow-Stewart K, et al. Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing. Oncol Nurs Forum. 2012;39:E101–11.PubMedCrossRef
50.
Wevers MR, Ausems MG, Verhoef S, Bleiker EM, Hahn DE, Hogervorst FB, et al. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer. 2011;11:6.PubMedCrossRefPubMedCentral
51.
52.
James KM, Cowl CT, Tilburt JC, Sinicrope PS, Robinson ME, Frimannsdottir KR, et al. Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. Mayo Clin Proc. 2011;86:933–40.PubMedCrossRefPubMedCentral
53.
Wakefield CE, Ratnayake P, Meiser B, Suthers G, Price MA, Duffy J, et al. “For all my family’s sake, I should go and find out”: an Australian report on genetic counseling and testing uptake in individuals at high risk of breast and/or ovarian cancer. Genet Test Mol Biomarkers. 2011;15:379–85.PubMedCrossRef
54.
Morgan D, Sylvester H, Lucas FL, Miesfeldt S. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer. 2009;8:277–87.PubMedCrossRef
55.
56.
Fraser L, Bramald S, Chapman C, Chu C, Cornelius V, Douglas F, et al. What motivates interest in attending a familial cancer genetics clinic? Fam Cancer. 2003;2:159–68.PubMedCrossRef
57.
Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S. Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach. Genet Test Mol Biomarkers. 2011;15:69–77.PubMedCrossRef
58.
Rolnick SJ, Rahm AK, Jackson JM, Nekhlyudov L, Goddard KA, Field T, et al. Barriers in identification and referral to genetic counseling for familial cancer risk: the perspective of genetic service providers. J Genet Couns. 2011;20:314–22.PubMedCrossRef
59.
Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol. 2012;2012:298745. doi:10.​1155/​2012/​298745.PubMedCrossRefPubMedCentral
60.
Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, Merajver SD. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not. Oncol Nurs Forum. 2011;38:572–81.PubMedCrossRef
61.
Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729–36.PubMedCrossRef
62.
Susswein LR, Skrzynia C, Lange LA, Booker JK, Graham ML 3rd, Evans JP. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. J Clin Oncol. 2008;26:32–6.PubMedCrossRef
63.
Chin TM, Tan SH, Lim SE, Iau P, Yong WP, Wong SW, et al. Acceptance, motivators, and barriers in attending breast cancer genetic counseling in Asians. Cancer Detect Prev. 2005;29:412–8.PubMedCrossRef
64.
Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH. Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Fam Cancer. 2011;10:199–205.PubMedCrossRef
65.
Genetic Information Non-Discrimination Act of 2008. H.R. 493, 110th Cong; 2007–2008.
66.
Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol. 2002;20(2):528–37.PubMedCrossRef
67.
Bando H, Shimizu C, Yamamoto S, Mizota Y, Katou T. Current situation survey on provision of information about hereditary breast cancer by Japanese physician to young breast cancer patients [abstract] J Japan Soc. Clin Oncol. 2011;452:MS1–6.
68.
Sugano K, Nakamura S, Ando J, Takayama S, Kamata H, Sekiguchi I, et al. Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Cancer Sci. 2008;99:1967–76.PubMedCrossRef
69.
Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat. 2012;134:353–62.PubMedCrossRef
70.
Metadata
Title
Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan
Author
Hiroko Bando
Publication date
01-11-2014
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-013-0477-z

Other articles of this Issue 6/2014

Breast Cancer 6/2014 Go to the issue

Rapid Communication

Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy

Letter to the Editor

Re: Comparison of conventional and automated breast volume ultrasound in the description and characterization of solid breast masses based on BI-RADS features

Original Article

Immediate transverse rectus abdominis musculocutaneous (TRAM) flap breast reconstruction in underweight Asian patients

Original Article

Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR

Acknowledgment

Acknowledgement to reviewers 2014

Original Article

Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits